Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling

• Published in: Mutation research Vol. 827; p. 111831
• Main Authors: Özdemir, Zeynep, Çevik, Ezgi, Öksüzoğlu, Ömür Berna Çakmak, Doğan, Mutlu, Ateş, Öztürk, Esin, Ece, Bilgetekin, İrem, Demirci, Umut, Köseoğlu, Çağlar, Topal, Alper, Karadurmuş, Nuri, Erdem, Haktan Bağış, Bahsi, Taha
• Format: Journal Article
• Language: English
• Published: Netherlands 01-07-2023
• Subjects: BRCA1 Protein - genetics; BRCA2 Protein - genetics; Breast Neoplasms - genetics; Female; Genetic Counseling; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Male; Multigene panel testing; Hereditary cancer syndromes; Next generation sequencing
• ISSN: 1873-135X
• DOI: 10.1016/j.mrfmmm.2023.111831

Hereditary cancer syndromes constitute 5-10% of all cancers. The development of next-generation sequencing technologies has made it possible to examine many hereditary cancer syndrome-causing genes in a single panel. This study's goal was to describe the prevalence and the variant spectrum using NGS in individuals who were thought to have a hereditary predisposition for cancer.
Analysis was performed for 1254 who were thought to have a familial predisposition for cancer. We excluded 46 patients who were carrying BRCA1/2 variants in this study, for focusing on the rare gene mutations. Sequencing was performed using the Sophia Hereditary Cancer Solution v1.1 Panel and the Qiagen Large Hereditary Cancer Panel. The Illumina MiSeq system was used for the sequencing procedure. The software used for the data analyses was Sophia DDM and QIAGEN Clinical Insight (QCITM) Analyze. The resulting genomic changes were classified according to the current guidelines of ACMG/AMP.
Pathogenic/likely pathogenic variants were detected in 172 (13.7%) of 1254 patients. After excluding the 46 BRCA1/2-positive patients, among the remaining 126 patients; there were 60 (4.8%) breast cancer, 33 (2.6%) colorectal cancer, 9 (0.7%) ovarian cancer, 5 (0.4%) endometrium cancer, 5 (0.4%) stomach cancer, 3 (0.2%) prostate cancer patients. The most altered genes were MUTYH in 27 (2.1%) patients, MMR genes (MLH1, MSH6, MSH, MSH2, PMS2 and EPCAM) in 26 (2%) patients, and ATM in 25 (2%) patients. We also examined the genotype-phenotype correlation in rare variants. Additionally, we identified 11 novel variations.
This study provided significant information regarding rare variants observed in the Turkish population because it was carried out with a large patient group. Personalized treatment options and genetic counseling for the patients are therefore made facilitated.